Live feed08:00:00·1183dPRReleasevia QuantisnowBiomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28ByQuantisnow·Wall Street's wire, on your screen.BMEA· Biomea Fusion Inc.Health Care
